TY  - JOUR
A1  - Schrewe, L.
A1  - Lill, C. M.
A1  - Liu, T.
A1  - Salmen, A.
A1  - Gerdes, L. A.
A1  - Guillot-Noel, L.
A1  - Akkad, D. A.
A1  - Blaschke, P.
A1  - Graetz, C.
A1  - Hoffjan, S.
A1  - Kroner, A.
A1  - Demir, S.
A1  - Böhme, A.
A1  - Rieckmann, P.
A1  - El Ali, A.
A1  - Hagemann, N.
A1  - Hermann, D. M.
A1  - Cournu-Rebeix, I.
A1  - Zipp, F.
A1  - Kümpfel, T.
A1  - Buttmann, M.
A1  - Zettl, U. K.
A1  - Fontaine, B.
A1  - Bertram, L.
A1  - Gold, R.
A1  - Chan, A.
T1  - Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS
JF  - Journal of Neuroinflammation
N2  - Background: Despite pleiotropic immunomodulatory effects of apolipoprotein E (apoE) in vitro, its effects on the clinical course of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) are still controversial. As sex hormones modify immunomodulatory apoE functions, they may explain contentious findings. This study aimed to investigate sex-specific effects of apoE on disease course of EAE and MS. 
Methods: MOG\(_{35-55}\) induced EAE in female and male apoE-deficient mice was assessed clinically and histopathologically. apoE expression was investigated by qPCR. The association of the MS severity score (MSSS) and APOE rs429358 and rs7412 was assessed across 3237 MS patients using linear regression analyses. 
Results: EAE disease course was slightly attenuated in male apoE-deficient (apoE\(^{-/-}\)) mice compared to wildtype mice (cumulative median score: apoE\(^{-/-}\) = 2 [IQR 0.0-4.5]; wildtype = 4 [IQR 1.0-5.0]; n = 10 each group, p = 0.0002). In contrast, EAE was more severe in female apoE\(^{-/-}\) mice compared to wildtype mice (cumulative median score: apoE\(^{-/-}\) = 3 [IQR 2.0-4.5]; wildtype = 3 [IQR 0.0-4.0]; n = 10, p = 0.003). In wildtype animals, apoE expression during the chronic EAE phase was increased in both females and males (in comparison to naive animals; p < 0.001). However, in MS, we did not observe a significant association between MSSS and rs429358 or rs7412, neither in the overall analyses nor upon stratification for sex. 
Conclusions: apoE exerts moderate sex-specific effects on EAE severity. However, the results in the apoE knock-out model are not comparable to effects of polymorphic variants in the human APOE gene, thus pinpointing the challenge of translating findings from the EAE model to the human disease.
KW  - immune
KW  - apoE
KW  - gender
KW  - inflammation
KW  - association studies in genetics
KW  - apoe
KW  - CNS disease
KW  - system
KW  - multiple sclerosis
KW  - MSSS
KW  - experimental autoimmune encephalomyelitis
KW  - disease severity
KW  - cognitive function
KW  - Alzheimer disease
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136252
VL  - 12
IS  - 234
ER  - 
TY  - JOUR
A1  - Mousset, Sabine
A1  - Buchheidt, Dieter
A1  - Heinz, Werner
A1  - Ruhnke, Markus
A1  - Cornely, Oliver A.
A1  - Egerer, Gerlinde
A1  - Krüger, William
A1  - Link, Hartmut
A1  - Neumann, Silke
A1  - Ostermann, Helmut
A1  - Panse, Jens
A1  - Penack, Olaf
A1  - Rieger, Christina
A1  - Schmidt-Hieber, Martin
A1  - Silling, Gerda
A1  - Südhoff, Thomas
A1  - Ullmann, Andrew J.
A1  - Wolf, Hans-Heinrich
A1  - Maschmeyer, Georg
A1  - Böhme, Angelika
T1  - Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
JF  - Annals of Hematology
N2  - Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.
KW  - cancer
KW  - invasive fungal infections
KW  - antifungals
KW  - mycoses
KW  - hematologic malignancies
KW  - aspergillosis
KW  - antifungal agents
KW  - invasive candidiasis
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121340
VL  - 96
ER  -